A Phase 1 Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Ascending Doses of PGN-EDODM1 in Adult Participants With Myotonic Dystrophy Type 1 (FREEDOM-DM1)
Latest Information Update: 09 Jun 2025
At a glance
- Drugs PGN-EDODM1 (Primary)
- Indications Myotonic dystrophy
- Focus Adverse reactions; Proof of concept
- Acronyms FREEDOM-DM1
- Sponsors Pepgen Corporation
Most Recent Events
- 03 Jun 2025 Planned End Date changed from 1 Apr 2025 to 1 Oct 2025.
- 03 Jun 2025 Planned primary completion date changed from 1 Apr 2025 to 1 Jun 2025.
- 28 May 2025 According to a Pepgen Corporation media release, company expect to report data from its FREEDOM-DM1 15 mg/kg cohort in patients with DM1 during the second half of 2025 and company expects to report data from the 5 mg/kg cohort of its FREEDOM2-DM1 study in DM1 patients in the first quarter of 2026.